# Rifampicin at High Dose for Difficult-to-Treat Tuberculosis

> **NCT04768231** · PHASE2 · UNKNOWN · sponsor: **Hospital Universitari Vall d'Hebron Research Institute** · enrollment: 130 (estimated)

## Conditions studied

- Tuberculosis

## Interventions

- **DRUG:** Rifampin

## Key facts

- **NCT ID:** NCT04768231
- **Lead sponsor:** Hospital Universitari Vall d'Hebron Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-01
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2021-02-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04768231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04768231, "Rifampicin at High Dose for Difficult-to-Treat Tuberculosis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04768231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*